Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rezetamig
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Rezetamig (JNJ-75348780) is a human bispecific antibody designed to target both CD3 on T cells and CD22 on B-lineage tumor cells. By binding to these two antigens, the drug brings T cells into close proximity with malignant B cells, leading to T-cell activation, cytokine induction, and subsequent cytotoxicity against the cancerous B cells. This mechanism leverages antibody-dependent cell cytotoxicity and direct stimulation of T lymphocytes. Rezetamig is being developed primarily for the treatment of B-cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The drug was originally discovered by TeneoBio and is currently being developed by Janssen Biotech/Janssen Research & Development[1][2][3][4][7].
- Brand names
- rezetamig
- Other names
- CD3 x CD22 bispecific antibodyCD-3 x CD22 bispecific antibodyCD 3 x CD22 bispecific antibody
02
Targets
CD22 (Cluster of Differentiation 22)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on rezetamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rezetamig.